drugset / Trial / NCT06333899
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with chemotherapy or after radiation therapy.
Timeline
- Start
- 2025-08-03
- Primary completion
- 2029-07-01
- Completion
- 2035-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lorlatinib | Small molecule | 115 mg/m2 | Oral |
| Subject | Lorlatinib | Small molecule | 150 mg | Oral |